glp-1 agonists and pancreatitis Risk of pancreatic cancer associated with receptor agonist therapy GLP-1–Based Therapy for Diabetes: What
Description
Dual and triple agonist therapies currently in development may expand the number of future pharmacotherapy options
Not everyone needs or tolerates a GLP-1
& Silvestre, L
A 2025 study published in Obesity found that GLP1 users lost 7.7% of body weight on semaglutide and 12.4% on tirzepatide after one year, roughly half the weight loss seen in randomized trials
A gastrointestinal (GI) hormone, GLP-1, and a gastric inhibitory peptide, GIP, are secreted in response to food consumption
